Long-term outcomes in Juvenile Myositis patients.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
02 2020
Historique:
received: 04 03 2019
revised: 10 06 2019
accepted: 21 06 2019
pubmed: 16 7 2019
medline: 5 2 2021
entrez: 16 7 2019
Statut: ppublish

Résumé

Juvenile idiopathic inflammatory myopathies (JIIM) are rare, chronic autoimmune muscle diseases of childhood, with the potential for significant morbidity. Data on long-term outcomes is limited. In this study we investigate correlations between clinical and demographic features with long-term outcomes in a referral population of adult patients with JIIM. Forty-nine adults with JIIM were assessed at two referral centers between 1994 and 2016. Features of active disease and damage at a cross-sectional assessment were obtained. Regression modeling was used to examine factors associated with long-term outcomes, defined by the presence of calcinosis or a higher adjusted Myositis Damage Index (MDI) score. A multivariable model of MDI was constructed using factors that were statistically significant in bivariate models. At a median of 11.5 [IQR 4.5-18.9] years following diagnosis, median American College of Rheumatology (ACR) functional class was 2 [1.5-3.0], Health Assessment Questionnaire (HAQ) score was 0.4 out of 3.0 [0.0-1.0], and manual muscle testing (MMT) score was 229 out of 260 [212.6-256.8]. Median MDI score was 6.0 [3.5-8.9], with the most commonly damaged organ systems being cutaneous and musculoskeletal. Factors associated with an elevated MDI score were the presence of erythroderma and other cutaneous manifestations, disease duration, and ACR functional class. Calcinosis was present in 55% of patients. The strongest predictors of calcinosis were disease duration, periungual capillary changes, and younger age at diagnosis. In a tertiary referral population, long-term functional outcomes of JIIM are generally favorable, with HAQ scores indicative of mild disability. Although most patients had mild disease activity and virtually all had significant disease damage, severe or systemic damage was rare. Certain clinical features are associated with long-term damage and calcinosis.

Identifiants

pubmed: 31303436
pii: S0049-0172(19)30136-2
doi: 10.1016/j.semarthrit.2019.06.014
pmc: PMC6934928
mid: NIHMS1535696
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-155

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001877
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA ES101081-17
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 ES999999
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES101074
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001876
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Références

Pediatr Rheumatol Online J. 2022 Nov 16;20(1):102
pubmed: 36384526
J Pediatr. 2018 Apr;195:16-27
pubmed: 29576174
Arthritis Rheum. 2006 Nov;54(11):3682-9
pubmed: 17075819
Arthritis Rheum. 2008 Nov;58(11):3585-92
pubmed: 18975314
Arthritis Rheumatol. 2016 Mar;68(3):761-8
pubmed: 26474155
Rheumatology (Oxford). 2014 Dec;53(12):2204-8
pubmed: 24987158
J Pediatr. 2017 May;184:38-44.e1
pubmed: 28410093
Scand J Rheumatol. 2012 Feb;41(1):50-8
pubmed: 22044089
Arthritis Rheumatol. 2016 Nov;68(11):2806-2816
pubmed: 27214289
Rheumatology (Oxford). 2008 Mar;47(3):324-8
pubmed: 18238791
Semin Arthritis Rheum. 2018 Dec;48(3):513-522
pubmed: 29773230
Rev Bras Reumatol. 2012 Aug;52(4):549-53
pubmed: 22885422
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57
pubmed: 22588740
J Pediatr. 2011 Nov;159(5):795-801
pubmed: 21784434
Arthritis Care Res (Hoboken). 2014 May;66(5):732-40
pubmed: 24151254
Rheumatology (Oxford). 2014 Sep;53(9):1578-85
pubmed: 24692575
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1103-11
pubmed: 20506141
Arthritis Rheum. 2009 Nov;60(11):3425-35
pubmed: 19877055
Medicine (Baltimore). 2008 Mar;87(2):70-86
pubmed: 18344805
Clin Exp Rheumatol. 2011 Jan-Feb;29(1):117-24
pubmed: 21345298
Arthritis Rheum. 2010 May;62(5):1533-8
pubmed: 20213809
Arthritis Care Res (Hoboken). 2012 Jul;64(7):1020-7
pubmed: 22328537
Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):63-72
pubmed: 20191492
Arthritis Rheum. 2008 Feb;58(2):571-6
pubmed: 18240225
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
J Clin Invest. 1993 Jun;91(6):2556-64
pubmed: 8514867
Medicine (Baltimore). 2013 Jul;92(4):223-243
pubmed: 23877355
Rheum Dis Clin North Am. 2013 Nov;39(4):877-904
pubmed: 24182859
Rheumatology (Oxford). 2011 May;50(5):885-93
pubmed: 21156669
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199

Auteurs

Vladislav Tsaltskan (V)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States.

Annette Aldous (A)

Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, United States.

Sam Serafi (S)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States.

Anna Yakovleva (A)

Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, United States.

Heidi Sami (H)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States.

Gulnara Mamyrova (G)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States.

Ira N Targoff (IN)

Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, United States; Oklahoma Medical Research Foundation, Oklahoma City, OK, United States.

Adam Schiffenbauer (A)

Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, United States.

Frederick W Miller (FW)

Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, United States.

Samuel J Simmens (SJ)

Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, United States.

Rodolfo Curiel (R)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States.

Olcay Y Jones (OY)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States; Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, United States.

Lisa G Rider (LG)

Division of Rheumatology, Department of Medicine, George Washington University, Washington, DC, United States; Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, United States. Electronic address: riderl@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH